Skip Navigation



European Heart Journal Advance Access published online on November 5, 2007
European Heart Journal, doi:10.1093/eurheartj/ehm493
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
28/23/2830    most recent
ehm493v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Haehling, S. v.
Right arrow Articles by Anker, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haehling, S. v.
Right arrow Articles by Anker, S. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2007. For permissions please email: journals.permissions@oxfordjournals.org

Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon?

Stephan von Haehling1,2,*, Mitja Lainscak1,3 and Stefan D. Anker1,2

1 Division of Applied Cachexia Research, Department of Cardiology, Campus Virchow Clinic, Charité–Universitätsmedizin Berlin, Germany
2 Department of Clinical Cardiology, National Heart & Lung Institute, Imperial College School of Medicine, London, UK
3 University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia

* Corresponding author. Tel: +49 30 450 553399; fax: +49 30 450 553951. E-mail address: s.vonhaehling03@imperial.ac.uk

This editorial refers to ‘Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial’ by C. Torp-Pedersen et al., doi:10.1093/eurheartj/ehm217

The first 10% of the full text of this article appears below.

Imagine your favourite pizza, and, after half of it is gone, your desire to eat the rest is gone as well. Sibutramine seems to have just this effect—at least for some. Doesn't this appear like the ideal scenario for losing weight? We and other authors are not so sure about that.1 Sibutramine, a centrally acting monoamino (noradrenaline and serotonin) reuptake inhibitor, was originally developed as an antidepressant. Due to its ‘side effect’ of moderate weight loss mainly achieved via increased satiety, the drug was approved and introduced into the US market in 1997, and is today licensed worldwide for the treatment of obesity.

The World Health Organization (WHO) estimates that currently there are >1 billion overweight adults worldwide, and that 300 million of them are clinically obese.2 Indeed, it can be said that obesity has reached epidemic proportions. Some people have approached . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial
Christian Torp-Pedersen, Ian Caterson, Walmir Coutinho, Nick Finer, Luc Van Gaal, Aldo Maggioni, Arya Sharma, Wygenia Brisco, Roger Deaton, Gillian Shepherd, Philip James, and on the behalf of the SCOUT Investigators
EHJ 2007 28: 2915-2923. [Abstract] [Full Text]